Previous studies showed that knockdown of SIRT6 can inhibit MAPK/ERK and PI3K/AKT/mTOR signaling pathways in hepatocellular carcinoma and diffuse large B-cell lymphoma [32, 33]. Here, AKT1 is linked to diffuse large B-cell lymphoma.